2020

1. Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy

   Ocular Immunology and Inflammation, pp. 1-8

2. Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioÚvea) Study Group

   Ophthalmology